Literature DB >> 757963

Determination of molsidomine in plasma by high-performance liquid column chromatography.

D Dell, J Chamberlain.   

Abstract

A high-performance liquid chromatographic method is described for the analysis of the anti-anginal compound 5-ethoxycarbonyl-3-morpholinosydnonimine (Molsidomine) in human and dog plasma. The drug was extracted from plasma into chloroform and the analysis was carried out on a reversed-phase column, the column effluent being monitored by UV absorption at 312 nm. The method is sensitive (2 +/- 0.3 ng/ml) and specific. The method was applied to a study in which human volunteers received an aqueous solution of the drug and then, on a separate occasion, a tablet formulation. Peak plasma levels of 20--30 ng/ml (tablet) and 10--19 ng/ml (aqueous solution) were obtained following a 2-mg oral dose.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 757963     DOI: 10.1016/s0378-4347(00)81205-0

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Pharmacokinetic profile of a novel slow release preparation of molsidomine.

Authors:  S Rietbrock; B Keller-Stanislawski; P Thürmann; D Brockmeier
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Mean time and first-pass metabolism.

Authors:  D Brockmeier; J Ostrowski
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.

Authors:  R Bergstrand; A Vedin; C Wilhelmsson; L E Peterson; J Chamberlain; D Dell; L A Stevens; J Ostrowski
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Clinical pharmacokinetics of molsidomine.

Authors:  B Rosenkranz; B R Winkelmann; M J Parnham
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

5.  Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.

Authors:  J Ostrowski; G Gaul; D Voegele; D Brockmeier; K Resag
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Molsidomine prevents post-ischaemic ventricular fibrillation in dogs.

Authors:  J P Cano; J C Guillen; R Jouve; F Langlet; P E Puddu; P H Rolland; A Serradimigni
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.